Cited 4 times in
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2021-09-29T02:24:04Z | - |
dc.date.available | 2021-09-29T02:24:04Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184868 | - |
dc.description.abstract | Purpose: Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. Methods: We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive [tumor proportion score (TPS) ≥ 10% by the SP263 assay or ≥ 50% by the 22C3 assay] R/M-NSCLC treated with pembrolizumab or nivolumab after failure of platinum-based chemotherapy. Results: The median age was 67 years, 13% of patients had ECOG-PS ≥ 2, and 27% were never-smokers. Adenocarcinoma was predominant (61%) and 18.1% harbored an EGFR activating mutation or ALK rearrangement. Pembrolizumab and nivolumab were administered to 51.3% and 48.7, respectively, and 42% received them beyond the third-line chemotherapy. Objective response rate (ORR) was 28.6%. Pembrolizumab group showed numerically higher ORR (30.7%) than the nivolumab group (26.4%), but it was comparable with that of the nivolumab group having PD-L1 TPS ≥ 50% (32.4%). Median progression-free survival (PFS) and overall survival (OS) were 2.9 (95% CI 0-27.9) and 10.7 months (95% CI 0-28.2), respectively. In multivariable analysis, concordance of TPS ≥ 50% in both PD-L1 assays and the development of immune-related adverse events (irAEs) were two significant predictors of better ORR, PFS, and OS. EGFR mutation could also predict significantly worse OS outcomes. Conclusion: The real-world benefit of later-line anti-PD1 antibodies was comparable to clinical trials in patients with R/M-NSCLC, although patients generally were more heavily pretreated and had poorer ECOG-PS. Concordantly high PD-L1 TPS ≥ 50% and development of irAE could independently predict better treatment outcomes, while EGFR mutation negatively affected OS. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English, German | - |
dc.publisher | Springer-Verlag | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Monoclonal / therapeutic use | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / therapeutic use | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / therapeutic use* | - |
dc.subject.MESH | B7-H1 Antigen / genetics | - |
dc.subject.MESH | B7-H1 Antigen / metabolism | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / mortality | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / pathology | - |
dc.subject.MESH | Cisplatin / therapeutic use* | - |
dc.subject.MESH | Drug Resistance, Neoplasm* / drug effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms / drug therapy* | - |
dc.subject.MESH | Lung Neoplasms / genetics | - |
dc.subject.MESH | Lung Neoplasms / mortality | - |
dc.subject.MESH | Lung Neoplasms / pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local / diagnosis | - |
dc.subject.MESH | Neoplasm Recurrence, Local / genetics | - |
dc.subject.MESH | Neoplasm Recurrence, Local / metabolism | - |
dc.subject.MESH | Nivolumab / therapeutic use | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Programmed Cell Death 1 Receptor / immunology* | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji Hyun Park | - |
dc.contributor.googleauthor | Gun Lyung You | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Sang-We Kim | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Ji-Youn Han | - |
dc.contributor.googleauthor | Chan-Young Ock | - |
dc.contributor.googleauthor | Jong-Seok Lee | - |
dc.contributor.googleauthor | In Jae Oh | - |
dc.contributor.googleauthor | Shin Yup Lee | - |
dc.contributor.googleauthor | Cheol Hyeon Kim | - |
dc.contributor.googleauthor | Young Joo Min | - |
dc.contributor.googleauthor | Yoon Hee Choi | - |
dc.contributor.googleauthor | Jeong-Seon Ryu | - |
dc.contributor.googleauthor | Sun Hyo Park | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Byoung-Yong Shim | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Sung Yong Lee | - |
dc.contributor.googleauthor | Jin-Soo Kim | - |
dc.contributor.googleauthor | Jiun Yi | - |
dc.contributor.googleauthor | Su Kyung Choi | - |
dc.contributor.googleauthor | Hyonggin An | - |
dc.contributor.googleauthor | Jin Hyoung Kang | - |
dc.identifier.doi | 10.1007/s00432-021-03527-4 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J01283 | - |
dc.identifier.eissn | 1432-1335 | - |
dc.identifier.pmid | 33523301 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00432-021-03527-4 | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | Immune-checkpoint inhibitor | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Real-world | - |
dc.subject.keyword | irAE | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 147 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2459 | - |
dc.citation.endPage | 2469 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.147(8) : 2459-2469, 2021-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.